A new review published in Cancer Biology & Medicine examines the role of tumor-expressed MHC-II in cancer immunotherapy. The study, conducted by researchers from Zhejiang Cancer Hospital and the Hangzhou Institute of Medicine at the Chinese Academy of Sciences, provides a detailed analysis of how MHC-II expression on tumor cells affects immune responses and treatment outcomes.
The review explains that while MHC-I is well known for its part in antigen presentation and immune surveillance, less attention has been given to MHC-II. Recent research shows that tumor cell MHC-II not only reflects the immune environment but also directs CD4⁺ T-cell activation, influencing both the quality and durability of antitumor immunity. The authors state that understanding how tumors regulate MHC-II is important for improving cancer immunotherapy.
According to the publication, "Recent findings indicate that tumor-expressed MHC-II not only reflects the immune environment but actively directs CD4⁺ T-cell activation, shaping the quality and durability of antitumor immunity. Its involvement in therapeutic resistance and treatment outcomes highlights the need to better understand its regulatory mechanisms and functional implications."
The study integrates molecular, cellular, and multi-omics data to describe how tumor-specific MHC-II (tsMHC-II) modulates CD4⁺ T-cell responses. It identifies both intrinsic oncogenic signaling pathways—such as MAPK and NF-κB—and extrinsic cytokines like IFN-γ as regulators of tsMHC-II expression through their effects on CIITA, a transcriptional activator. This regulation allows tumor cells to present antigens directly to CD4⁺ T cells.
The authors write: "Mechanistically, tsMHC-II is controlled by intrinsic oncogenic signaling, including MAPK and NF-κB pathways, which modulate the transcriptional activator CIITA. Extrinsic cytokines—most notably IFN-γ—further enhance MHC-II induction, allowing tumor cells to directly present antigens to CD4⁺ T cells."
The review notes that higher levels of tsMHC-II can increase tumor immunogenicity by enabling direct neoantigen presentation and amplifying systemic immune activation. Conversely, reduced or lost expression may help tumors evade immune detection and limit response to checkpoint inhibitors.
Multi-omics approaches such as single-cell RNA sequencing have revealed significant variation in tsMHC-II expression among different cancers. This heterogeneity could be useful for patient stratification when selecting treatments.
"Together, these findings elevate tsMHC-II from a passive marker to an active determinant of immunotherapy outcomes," according to the authors. They suggest that targeting or measuring tsMHC-II could serve as both a predictive biomarker for therapy selection and a therapeutic target itself.
The authors emphasize: "Unraveling how tumors regulate MHC-II expression is essential for guiding the next phase of immunotherapy innovation." They add that integrating multi-omics data will be important for developing robust biomarkers based on MHC-II status.
Modulating MHC-II could improve patient selection for therapies such as checkpoint inhibitors while potentially reducing side effects through more precise immune activation strategies. The review concludes that incorporating knowledge about tsMHC-II into clinical practice may lead to more effective personalized cancer treatments.
